High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome

Qi Liu; Shuo Yang; Yuan Tan; Liyan Cui

doi:10.3389/fimmu.2023.1128245

High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome

Front Immunol. 2023 May 19:14:1128245. doi: 10.3389/fimmu.2023.1128245. eCollection 2023.

Authors

Qi Liu^{1

2

3}, Shuo Yang^{1

2}, Yuan Tan^{1

2

3}, Liyan Cui^{1

2}

Affiliations

¹ Department of Clinical Laboratory, Peking University Third Hospital, Beijing, China.
² Core Unit of National Clinical Research Center for Laboratory Medicine, Peking University Third Hospital, Beijing, China.
³ Institute of Medical Technology, Peking University Health Science Center, Beijing, China.

Abstract

Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and/or morbid pregnancy, accompanied by persistent antiphospholipid antibody (aPL) positivity. However, due to the complex pathogenesis of APS and the large individual differences in the expression of aPL profiles of patients, the problem of APS diagnosis, prognosis judgment, and risk assessment may not be solved only from the antibody level. It is necessary to use new technologies and multiple dimensions to explore novel APS biomarkers. The application of next-generation sequencing (NGS) technology in diseases with a high incidence of somatic mutations, such as genetic diseases and tumors, has been very mature. Thus, we try to know the research and application progress of APS by NGS technology from genome, transcriptome, epigenome and other aspects. This review will describe the related research of NGS technology in APS and provide more reference for the deep understanding of APS-related screening markers and disease pathogenesis.

Keywords: antiphospholipid syndrome; biomarkers; diagnosis; next-generation sequencing; prognosis.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Antiphospholipid
Antiphospholipid Syndrome* / complications
Antiphospholipid Syndrome* / diagnosis
Antiphospholipid Syndrome* / genetics
Biomarkers
Female
High-Throughput Nucleotide Sequencing
Humans
Pregnancy
Thrombosis*

Substances

Antibodies, Antiphospholipid
Biomarkers

Grants and funding

This work was supported by the National Natural Science Foundation of China (62071011), Key Clinical Specialty Funding Project of Beijing and Hospital-Enterprise Joint Funding Project.